Skip to main content

Korro Bio, Inc.

KRRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001703647

In the last 90 days, Korro Bio, Inc. insiders filed 1 open-market purchase and 7 sales; 106 institutions reported holding it in 13F filings for Q2 2026, worth $190.1M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Korro Bio, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of KRRO: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders4240−2
Shares10.6M6.56M−4.04M (−38.1%)
Value$2.58M$301.5M+$298.9M (+11,572.0%)

New holders (16)

Institutions that held Korro Bio, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to KRRO in Q4 2023
InstitutionSharesValue% of portfolio
Atlas Venture Life Science Advisors, LLC1,119,292$53.6M6.39%
NEA Management Company, LLC1,072,936$41.1M2.74%
FMR LLC727,205$32.6M0.00%
Cormorant Asset Management, LP529,170$25.4M1.21%
Artal Group S.A.418,605$20.1M0.68%
Qiming U.S. Ventures Management, LLC368,085$17.6M16.15%
72 Investment Holdings, LLC276,831$13.3M58.92%
Point72 Asset Management, L.P.265,826$12.7M0.04%
Monashee Investment Management LLC90,805$4.35M0.77%
Suvretta Capital Management, LLC73,821$3.54M0.16%
Verition Fund Management LLC58,086$2.78M0.03%
Citigroup Inc17,007$815.1K0.00%
Jane Street Group, LLC7,365$353.0K0.00%
ExodusPoint Capital Management, LP5,610$269.0K0.00%
Tower Research Capital LLC (TRC)3,962$189.9K0.00%
City State Bank20$1.00K0.00%

Sold out (18)

Institutions that held Korro Bio, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.